Brainstorm cell therapeutics announces peer reviewed publication of results from the nurown® phase 2 progressive ms trial in multiple sclerosis journal

Data demonstrate nurown's safety and provide preliminary evidence of efficacy in patients with progressive multiple sclerosis biomarker analyses show consistent treatment effects in neuroinflammation and neuroprotection pathways new york , sept. 15, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer reviewed publication of data from the phase 2 trial of nurown in progressive multiple sclerosis (ms) in multiple sclerosis journal.
BCLI Ratings Summary
BCLI Quant Ranking